SCOPUS 정보 검색 플랫폼

Volumn 120, Issue 5 SUPPL., 2013, Pages

Implications of the comparisons of age-related macular degeneration treatments trials on clinical practice: What have we learned?

(1) Do, Diana V a

a JOHNS HOPKINS UNIVERSITY (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEVACIZUMAB; RANIBIZUMAB;

ARTICLE; CLINICAL PRACTICE; COMORBIDITY; COMPARATIVE STUDY; DRUG EFFICACY; DRUG SAFETY; ENDOPHTHALMITIS; GASTROINTESTINAL DISEASE; HEART FAILURE; HUMAN; MULTICENTER STUDY (TOPIC); OPTICAL COHERENCE TOMOGRAPHY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RETINA MACULA AGE RELATED DEGENERATION; SUBRETINAL NEOVASCULARIZATION; VISUAL ACUITY;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL, HUMANIZED; DRUG ADMINISTRATION SCHEDULE; HUMANS; MACULAR DEGENERATION; VISUAL ACUITY;

EID: 84876979351 PISSN: 01616420 EISSN: 15494713 Source Type: Journal
DOI: 10.1016/j.ophtha.2013.01.058 Document Type: Article

Times cited : (3)

References (7)

1
- 77952500113
- Current status of vascular endothelial growth factor inhibition in age-related macular degeneration
- S.A. Mousa, S.S. Mousa Current status of vascular endothelial growth factor inhibition in age-related macular degeneration BioDrugs 24 2010 183 194
- (2010) BioDrugs , vol.24 , pp. 183-194
- Mousa, S.A.¹ Mousa, S.S.²

2
- 79955085045
- Pharmacotherapy for neovascular age-related macular degeneration: An analysis of the 100% 2008 Medicare fee-for-service part B claims file
- e881
- R.J. Brechner, P.J. Rosenfeld, J.D. Babish Pharmacotherapy for neovascular age-related macular degeneration: an analysis of the 100% 2008 Medicare fee-for-service part B claims file Am J Ophthalmol 151 2011 887 895 e881
- (2011) Am J Ophthalmol , vol.151 , pp. 887-895
- Brechner, R.J.¹ Rosenfeld, P.J.² Babish, J.D.³

3
- 79956218863
- Ranibizumab and bevacizumab for neovascular age-related macular degeneration
- CATT Research Group
- CATT Research Group D.F. Martin, M.G. Maguire et al. Ranibizumab and bevacizumab for neovascular age-related macular degeneration N Engl J Med 364 2011 1897 1908
- (2011) N Engl J Med , vol.364 , pp. 1897-1908
- Martin, D.F.¹ Maguire, M.G.²

4
- 79952108783
- Evaluating equivalence and noninferiority trials
- A. Dasgupta, K.A. Lawson, J.P. Wilson Evaluating equivalence and noninferiority trials Am J Health Syst Pharm 67 2010 1337 1343
- (2010) Am J Health Syst Pharm , vol.67 , pp. 1337-1343
- Dasgupta, A.¹ Lawson, K.A.² Wilson, J.P.³

5
- 84863320414
- Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: Two-year results
- D.F. Martin, M.G. Maguire, S.L. Fine Ranibizumab and bevacizumab for treatment of neovascular age-related macular degeneration: two-year results Ophthalmology 119 2012 1388 1398
- (2012) Ophthalmology , vol.119 , pp. 1388-1398
- Martin, D.F.¹ Maguire, M.G.² Fine, S.L.³

6
- 84876964705
- National Eye Institute Accessed June 10, 2012
- National Eye Institute Avastin and Lucentis are equivalent in treating age-related macular degeneration http://www.nih.gov/news/health/apr2012/nei-30a. htm Accessed June 10, 2012
- Avastin and Lucentis Are Equivalent in Treating Age-related Macular Degeneration

7
- 84863327423
- Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: One-year findings from the IVAN Randomized Trial
- U. Chakravarthy, S.P. Harding, C.A. Rogers Ranibizumab versus bevacizumab to treat neovascular age-related macular degeneration: one-year findings from the IVAN Randomized Trial Ophthalmology 119 2012 1399 1411
- (2012) Ophthalmology , vol.119 , pp. 1399-1411
- Chakravarthy, U.¹ Harding, S.P.² Rogers, C.A.³

* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.